KRAS and cancer: For instance, in the NSCLC cancer PDX models LG1179 (Kras G13R) and LG0551 (squamous cell carcinoma), a single RN765C treatment at 1.5 mg/kg or 3.0 mg/kg, respectively, induces sustained tumor regression, while multiple doses of gemcitabine, carboplatin and paclitaxel either have no effect (carboplatin in LG1179) or only leads to tumor growth inhibition (Figure 5B and 5C).